Based on the unique properties of 212Pb, Orano Med is developing a multi asset portfolio to combine 212Pb with diverse biological vectors targeting or binding to different specific cancer receptors or antigens. Our pipeline is composed of a mix of partnered compounds and internal developments.
AlphaMedixTM is a somatostatin receptor targeting peptide radiolabeled with 212Pb. Somatostatin receptors are overexpressed in most neuroendocrine tumors, a heterogeneous group of rare neoplasms that originate from neuroendocrine cells. These neoplasms occur mostly in the gastrointestinal tract and pancreas, but can also occur in other tissues including thymus, lung, and other uncommon sites such as ovaries, heart, and prostate.
After the promising results of the Phase 1 clinical trial launched early 2018, a Phase 2 was initiated late 2021 to assess the efficacy of AlphamedixTM in the treatment of neuroendocrine tumors. The study is currently recruiting patients in the US.
Find out more :
(breast and prostate cancer)
Alpha 37 is a 212Pb-conjugated anti-CD37 antibody under development for the treatment of chronic lymphocytic leukemia, orphan diseases with still significant unmet medical needs. CD-37 is an interesting target as it is widely expressed in a number of hematological malignancies.
Orano Med has entered into a partnership with Crescendo Biologics in order to explore the benefits of use of VH antibodies in applications of Targeted Alpha Therapy.
Orano Med has developed a strong expertise in the development of radiopharmaceuticals using 212Pb and is looking for new partners willing to add one of the most powerful payloads to their biological vector. Vectors with high specific affinity, a fast accumulation in tumor tissues, and rapid excretion as well are of particular interest to us! Don't hesitate to contact us: email@example.com